|
05 Sep 2020 |
Genentech Announces FDA Approval of Gavreto (pralsetinib) for the Treatment of Adults With Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
|
|
04 Sep 2020 |
Syntekabio’s repurposed COVID-19 combination therapy shows notable animal efficacy
|
|
04 Sep 2020 |
89bio Initiates Phase 2 Trial of BIO89-100 in Patients with Severe Hypertriglyceridemia
|
|
04 Sep 2020 |
Relay Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Trial of RLY-4008, a Highly Selective FGFR2 Inhibitor
|
|
04 Sep 2020 |
Chi-Med Initiates FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer
|
|
04 Sep 2020 |
Bio-Thera Solutions Initiates Phase I Clinical Trial for BAT2206, a Proposed Biosimilar of Stelara® (Ustekinumab)
|
|
04 Sep 2020 |
Johnson & Johnson Announces that Janssen’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies
|
|
04 Sep 2020 |
Amylyx Pharmaceuticals Announces New England Journal of Medicine Publication of Pivotal AMX0035 Data Demonstrating Statistically Significant Benefit in People with ALS
|
|
04 Sep 2020 |
Alligator Bioscience presents positive biomarker data demonstrating proof of mechanism in mitazalimab clinical Phase I study
|
|
04 Sep 2020 |
Savara to Discontinue Exploratory ENCORE Study Evaluating Molgradex for the Treatment of NTM Lung Infection in People Living With Cystic Fibrosis (CF)
|
|
04 Sep 2020 |
Kite and HiFiBiO Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia
|
|
03 Sep 2020 |
Akebia Therapeutics Announces Top-Line Results from its PRO2TECT Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients Not on Dialysis
|
|
03 Sep 2020 |
Innovent Announces NMPA Granted Marketing Approval for SULINNO® (Adalimumab Injection) in China
|
|
03 Sep 2020 |
AEON Biopharma Announces FDA Acceptance of IND for ABP-450 as a Treatment for Cervical Dystonia; Secures $25 Million Investment
|
|
03 Sep 2020 |
Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
|
|
03 Sep 2020 |
Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Intrahepatic Cholangiocarcinoma in China
|
|
03 Sep 2020 |
Rain Therapeutics Announces License Agreement for the Development of Proprietary RAD52 Inhibitors in the DNA Damage Response Pathway
|
|
03 Sep 2020 |
Rain Therapeutics Announces Exclusive License to the Clinical-Stage MDM2 Inhibitor, DS-3032 (Milademetan) from Daiichi Sankyo
|
|
02 Sep 2020 |
BiomX Enters Collaboration with Boehringer Ingelheim with the Goal of Discovering Microbiome-Based Biomarkers for Inflammatory Bowel Disease
|
|
02 Sep 2020 |
Bicycle Therapeutics Announces First Patient Dosed in Phase IIa Trial of Bicycle® Toxin Conjugate BT1718
|
